Penile Cancer pN3 TNM Finding v7

description: Penile cancer with extranodal extension of lymph node metastasis or pelvic lymph node(s) unilateral or bilateral. (from AJCC 7th Ed.)


Penile Cancer pM1 TNM Finding v7

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: Penile cancer with distant metastasis (lymph node metastasis outside of the true pelvis in addition to visceral or bone sites). (from AJCC 7th Ed.)


Penile Cancer pT1b TNM Finding v7

description: Penile cancer with tumor invading subepithelial connective tissue with lymph vascular invasion or is poorly differentiated. (from AJCC 7th Ed.)


Penile Cancer pT2 TNM Finding v7

description: Penile cancer with tumor invading corpus spongiosum or cavernosum. (from AJCC 7th Ed.)


Penile Cancer pN2 TNM Finding v7

description: Penile cancer with metastasis in multiple or bilateral inguinal lymph nodes. (from AJCC 7th Ed.)


Penile Cancer pN1 TNM Finding v7

description: Penile cancer with metastasis in a single inguinal lymph node. (from AJCC 7th Ed.)


Retinoblastoma pM1c TNM Finding v7

description: CNS metastasis. (from AJCC 7th Ed.)


name: Retinoblastoma Pathologic Distant Metastasis TNM Finding v7

description: A pathologic finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0 for retinoblastoma. (from AJCC 7th Ed.)


Retinoblastoma pM1e TNM Finding v7

description: Leptomeningeal and/or CSF involvement. (from AJCC 7th Ed.)


Retinoblastoma pM1d TNM Finding v7

description: Discrete mass(es) without leptomeningeal and/or CSF involvement. (from AJCC 7th Ed.)


Retinoblastoma pM1a TNM Finding v7

description: Single lesion. (from AJCC 7th Ed.)


Retinoblastoma pM1 TNM Finding v7

description: Retinoblastoma with metastasis to sites other than CNS. (from AJCC 7th Ed.)


Retinoblastoma pM1b TNM Finding v7

description: Multiple lesions. (from AJCC 7th Ed.)


A secondary fatty alcohol that is henicosane substituted by a hydroxy group at position 2.


Grade 1 Scalp Pain, CTCAE

description: Mild pain


Cusp Doming Severity

description: The qualitative measurement of the severity of doming of a cardiac cusp.


name: Ocular Adnexal Lymphoma pN0 TNM Finding v7

description: No evidence of lymph node involvement. (from AJCC 7th Ed.)


name: 5-[4-[methyl-[(3-methyl-2-thiophenyl)methyl]amino]-6-quinazolinyl]-2-furancarboxylic acid ethyl ester


name: Type 2 Diabetes Mellitus with Mild Nonproliferative Diabetic Retinopathy with Macular Edema, Unspecified Eye

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: Evidence of type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema in an unspecified eye.


A dihydroceramide in which the ceramide N-acyl group is specified as (15Z)-tetracosenoyl (nervonoyl).


name: Childhood Cerebellar Anaplastic Astrocytoma

description: A cerebellar anaplastic astrocytoma that occurs during childhood.


sulcofuron-sodium

The sodium salt of sulcofuron.


morellic acid

A dioxo monocarboxylic acid derived from morellin by oxidation of the aldehyde group to the corresponding carboxy group. Isolated from Garcinia morella and Garcinia hanburyi, it exhibits antineoplastic, antibacterial and anti-HIV activity.


name: 3-(1,3-benzodioxol-5-yl)-2-propenoic acid [2-(cyclopropylamino)-2-oxoethyl] ester


1-Aminocyclopropane carboxylic acid

A non-proteinogenic alpha-amino acid consisting of cyclopropane having amino and carboxy substituents both at the 1-position.


name: Grade 2 Oral Cavity Pulmonary Fistula, CTCAE


A member of the class of monohydroxy-1,4-benzoquinones that is embelin in which the hydroxy group at position 5 is replaced by a methoxy group. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antileishmanial activity as well as inhibitory activity towards hepatitis C protease.


A 2-pyranone in which the hydrogens at positions 4 and 6 of 2H-pyran-2-one are replaced by hydroxy and 2-oxotridecyl groups respectively.


pApA

A 5'-phospho-(3'->5')-dinucleotide composed from two AMP residues.


A 4-hydroxy-D-proline in which the hydroxy group at position 4 has S-configuration.


Stage II Lip Cancer AJCC v6 and v7

description: Stage II includes: T2, N0, M0. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


D-xylonic acid

A xylonic acid with D configuration.


Lower Gingival Verrucous Carcinoma

description: A verrucous carcinoma of the oral cavity that arises from the lower gingiva.


name: Verrucous carcinoma of the oral cavity recurrent

description: Reemergence of verrucous carcinoma of the oral cavity after a period of remission.


Tongue Verrucous Carcinoma

description: A well differentiated squamous cell carcinoma arising from the tongue.  It is an exophytic, warty, slow growing tumor, usually affecting older males. It is associated with the chronic use of smokeless tobacco.


Buccal Mucosa Verrucous Carcinoma

description: A verrucous carcinoma of the oral cavity that arises from the buccal mucosa.


Oral Cavity Carcinoma Cuniculatum

description: A variant of well-differentiated squamous cell carcinoma arising from the oral cavity. It is characterized by the presence of minimal cytological atypia, multiple keratin-filled crypts, and intraepithelial neutrophils.


Upper Gingival Verrucous Carcinoma

description: A verrucous carcinoma of the oral cavity that arises from the upper gingiva.


Retinoblastoma pNX TNM Finding v8

description: Retinoblastoma in which regional lymph node involvement cannot be assessed.  (from AJCC 8th Ed.)


A carbohydrazide obtained by formal condensation of the carboxy group of 4-hydroxybenzoic acid with hydrazine.


The S-(trans-4-carboxybut-2-enoyl) derivative of coenzyme A.


(R)-methyl phenyl sulfoxide

A (methylsulfinyl)benzene that has R configuration at the chiral sulfur.


LYPD3 Positive

description: Indicates that LYPD3 expression has been detected in a sample.


Positive Laboratory Test Result

description: A laboratory test result that indicates that a specific disease, condition, or attribute being assessed is present.


BRAF Gene Alteration Positive

description: A finding indicating that mutation, amplification, overexpression or rearrangement of the BRAF gene has been detected in a sample.


MAPK Pathway Alteration Positive

description: A genetic finding indicating the presence of gene abnormalities resulting in alteration of signaling in the MAPK pathway.


ATM Proficient Tumor

description: A finding indicating that the expression and activity of ATM in a tumor sample is detected at or near normal levels.


NRG1 Gene Fusion Positive

description: An indication that the expression of a fusion containing sequences derived from the NRG1 gene has been detected in a sample.


PSCA Positive

description: An indication that PSCA expression has been detected in a sample.


MUC1 Positive

description: An indication that expression of MUC1 has been detected in a sample.


CD3 Positive

description: An indication that the CD3 complex has been detected in a sample.


Mesothelin Positive

description: Indicates that mesothelin expression has been detected in a sample.


RB1 Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the RB1 gene has been detected in a sample.


NOS2 Positive

description: Indicates that NOS2 expression has been detected in a sample.


Human Papillomavirus-18 Positive

description: An indication that human papillomavirus-18 has been detected in a sample.


NY-ESO-1 Positive Tumor Cells Present

description: An indication that Cancer/Testis Antigen 1 expression has been detected in a sample.


RSPO Gene Fusion Positive

description: Indicates that a fusion containing RSPO family gene sequences has been detected in a sample.


ALK Fusion Positive

description: An indication that ALK fusion expression has been detected in a sample.


name: Circulating Tumor-Derived DNA Mutation Positive

description: A genetic finding indicating the detection of mutations in the cell-free tumor-derived DNA that is present in a blood, serum or plasma sample.


Human Immunodeficiency Virus 1 Positive

description: Indicates that human immunodeficiency virus 1 has been detected in a sample.


ERBB2 Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the ERBB2 gene has been detected in a sample.


Folate Receptor Family Positive

description: An indication that expression of a member of the folate receptor family has been detected in a sample.


SS18/SSX Rearrangement Positive

description: An indication that rearrangement involving SS18 and one of three SSX family members (SSX1, SSX2 or SSX4) has been detected in a sample.


TNFRSF17 Positive

description: Indicates that TNFRSF17 expression has been detected in a sample.


CD1A Positive

description: An indication that CD1A expression has been detected in a sample.


name: HER2/Neu Positive by Immunohistochemistry 61-70 Percent

description: An immunohistochemical staining finding indicating that 61-70 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.


CCND1 Splice Variant Positive

description: An indication that expression of a splice variant of CCND1 has been detected in a sample.


MME Positive

description: An indication that MME expression has been detected in a sample.


Human Herpesvirus 2 DNA Positive

description: An indication that human herpesvirus 2 DNA has been detected in a sample.


HLA-B*44:03 Positive Cells Present

description: An indication that cells expressing HLA-B*44:03 have been detected in a sample.


CYP3A4 Polymorphism Positive

description: An indication that polymorphism of the CYP3A4 gene has been detected in a sample.


HLA-G Positive Cells Present

description: An indication that expression of HLA-G has been detected in a sample.


Monoclonal Langerhans Cells Present

description: An indication that monoclonal Langerhans cells were detected in a sample.


PTTG1 Positive

description: An indication that PTTG1 expression has been detected in a sample.


WT1 Positive

description: Indicates that WT1 expression has been detected in a sample.


AXL Gene Alteration Positive

description: A finding indicating that underexpression, overexpression, mutation, amplification, deletion, fusion or rearrangement involving the AXL gene has been detected in a sample.


name: FGFR1 Internal Tandem Duplication Positive

description: An indication that internal tandem duplication within the FGFR1 gene has been detected in a sample.


AKAP4 Positive

description: An indication that AKAP4 expression has been detected in a sample.


Folate Receptor Alpha Positive

description: An indication that folate receptor alpha has been detected in a sample.


MUC17 Positive

description: An indication that MUC17 expression has been detected in a sample.


IRAK1 Fusion Positive

description: Indicates that expression of a fusion containing sequences from IRAK1 has been detected in a sample.


Monoclonal Cellular Population Present

description: A finding indicating that a monoclonal population of cells were detected in a sample.


name: Estrogen Receptor-Positive and Progesterone Receptor-Positive

description: An indication that estrogen and progesterone receptors expression has been detected in a sample.


DICER1 Gene Alteration Positive

description: An indication that underexpression, overexpression, mutation, amplification, deletion, fusion or rearrangement involving the DICER1 gene has been detected in a sample.


EGFR Positive

description: An indication that EGFR expression has been detected in a sample.


66 kDa Phosphoprotein Antibody Positive

description: An indication that antibodies that recognize the CMV 65 kDa phosphoprotein have been detected in a sample.


Gene Variant Positive

description: An indication that gene variants were detected in a sample.


name: SARS Coronavirus 2 Spike Glycoprotein P681H Substitution Positive

description: An indication that expression of SARS coronavirus 2 spike glycoprotein where the proline at amino acid position 681 has been substituted with histidine has been detected in a sample.


t(15;17) Positive

description: A cytogenetic finding indicating that the translocation t(15;17) has been detected in a sample.


CA19-9 Greater than 500 U/mL

description: A semiquantitative finding indicating that the concentration of CA19-9 detected in a sample is greater than 500 U/mL.


NUTM1 Gene Fusion Positive

description: An indication that a NUTM1 fusion gene has been detected in a sample.


t(11;14) Positive

description: A cytogenetic finding indicating that the translocation t(11;14) has been detected in a sample.


FGFR3 Gene Alteration Positive

description: An indication that mutation, overexpression, fusion or rearrangement involving the FGFR3 gene has been detected in a sample.


Somatostatin Receptor 2 Positive

description: An indication that somatostatin receptor type 2 expression has been detected in a sample.


name: Pediatric Glioma RTK1 Molecular Signature Detected

description: An indication that the RTK1-type molecular signature for pediatric high grade glioma was detected in a sample. This signature occurs more frequently in supratentorial than infratentorial gliomas and co-occurs with expression of both wild-type histone H3 and wild-type IDH. The RTK1-type molecular signature is characterized by the following molecular abnormalities (in order of most to least frequent) TP53 gene mutation, PDGFRA gene amplification, homozygous deletion of chromosome 9p, MGMT promoter methylation and loss of ATRX protein expression. This signature may rarely include gain of chromosome 7, loss of chromosome 10q, CDK4/6 mutations and MYCN gene amplification. Additionally, EGFR gene amplification and TERT promoter mutation are not characteristics of this signature.


MAP3K8 Fusion Positive

description: An indication that expression of a fusion containing sequences from MAP3K8 has been detected in a sample.


MET Positive

description: Indicates that MET expression has been detected in a sample.


MYC Positive

description: Indicates that MYC expression has been detected in a sample.


name: HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain Positive

description: Indicates that HLA class I histocompatibility antigen, A-0201 alpha chain expression has been detected in a sample.


FSHR Positive

description: An indication that FSHR expression has been detected in a sample.


FGFR1 Positive

description: An indication that FGFR1 expression has been detected in a sample.


TNFRSF13C Positive

description: An indication that TNFRSF13C expression has been detected in a sample.


Non-BRCA Gene Mutation

description: A genetic finding indicating the presence of gene mutations in a sample that may be associated with cancer predisposition and are in located in genes other than BRCA1 and BRCA2.


SLFN12 Positive

description: An indication that SLFN12 expression has been detected in a sample.


FOLR2 Positive

description: An indication that folate receptor beta has been detected in a sample.


NTRK2 Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the NTRK2 gene has been detected in a sample.


CGAS Positive

description: An indication that expression of CGAS has been detected in a sample.


HA-1(H) Genotype Positive

description: A genetic finding indicating that a subject expresses the HA-1(H) genotype and has a homozygous or heterozygous nucleotide substitution at position 416 of the ARHGAP45 gene where the guanine has been mutated to adenine, which encodes a variant of Rho GTPase-activating protein 45 where the arginine at position 139 has been replaced by histidine. The HA-1(H) form of ARHGAP45 protein can be processed into a nonapeptide that can be presented by HLA-A*0201 and other HLA-A isoforms, while the peptide produced by processing the protein resulting from transcription of the ARHGAP45 gene with guanine at position 416, which will have arginine at amino acid residue 139 (HA-1(R)) cannot bind HLA-A.


IL2RA Positive

description: Indicates that IL2RA expression has been detected in a sample.


UGT1A1*1/*37 Positive

description: An indication that simultaneous expression of the *1 and *37 alleles of the UGT1A1 gene have been detected in a sample. This genotype is associated with intermediate levels of metabolic activity against bilirubin and various pharmacologic agents.


FGFR Family Alteration Positive

description: Indicates that mutation, overexpression or rearrangement of an FGFR family member has been detected in a sample.


name: SARS Coronavirus 2 Spike Glycoprotein Variant Positive

description: An indication that expression of SARS coronavirus 2 spike glycoprotein with an amino acid variation has been detected in a sample.


name: Activating JAK-STAT Pathway Positive Ph-Like B Acute Lymphoblastic Leukemia

description: A finding indicating that JAK-STAT pathway activating mutations or rearrangements have been detected in a patient with Ph-like B acute lymphoblastic leukemia. This finding is associated with a higher relapse risk and may amenable to treatment that utilizes JAK-STAT pathway inhibitors.


RB1 Positive

description: Indicates that RB1 expression has been detected in a sample.


UGT1A1*36/*28 Positive

description: An indication that simultaneous expression of the *36 and *28 alleles of the UGT1A1 gene have been detected in a sample. This genotype is associated with intermediate levels of metabolic activity against bilirubin and various pharmacologic agents.


MAGEA6 Positive

description: An indication that melanoma-associated antigen 6 expression has been detected in a sample.


YAP1 or WWTR1 Fusion Gene Positive

description: An indication that fusions involving either the YAP1 gene or the WWTR1 (TAZ) gene have been detected in a sample.


ABL Positive

description: Indicates that the expression of a member of the ABL family has been detected in a sample.


FGF1 Gene Fusion Positive

description: An indication that a FGF1 fusion gene has been detected in a sample.


CTNNB1 Positive

description: An indication that CTNNB1 expression has been detected in a sample.


name: SARS Coronavirus 2 Spike Glycoprotein K417N/T Substitution Positive

description: An indication that expression of SARS coronavirus 2 spike glycoprotein where the lysine at amino acid position 417 has been substituted with either asparagine or threonine has been detected in a sample.


ROS1 Positive

description: An indication that expression of ROS1 has been detected in a sample.


ALKATI Positive

description: An indication that expression of ALKATI has been detected in a sample.


PSMA-Positive Tumor

description: An indication that prostate-specific membrane antigen (PSMA) expression has been detected in a tumor sample.


ABCB11 Positive

description: An indication that ABCB11 expression has been detected in a sample.


HLA-A*03:01 Positive Cells Present

description: A laboratory test result indicating the presence of HLA-A*03:01 positive cells in a tissue sample.


AG7 Antigen Positive

description: An indication that expression of the tumor-associated antigen AG7 has been detected in a sample.


ABCB4 Positive

description: An indication that ABCB4 expression has been detected in a sample.


NTRK3 Fusion Positive

description: Indicates that the expression of a NTRK3 fusion has been detected in a sample.


HLA-A*0203 Positive Cells Present

description: An indication that cells expressing HLA-A*0203 have been detected in a sample.


t(4;14) Positive

description: A cytogenetic finding indicating that the translocation t(4;14) has been detected in a sample.


CD22 Positive

description: Indicates that CD22 expression has been detected in a sample.


ANPEP Positive

description: An indication that ANPEP expression has been detected in a sample.


KLB Positive

description: An indication that KLB expression has been detected in a sample.


CD86 Positive

description: An indication that expression of CD86 has been detected in a sample.


CLDN6 Positive

description: An indication that expression of CLDN6 has been detected in a sample.


CD33 Positive

description: Indicates that CD33 expression has been detected in a sample.


AKT Family Gene Alteration Positive

description: An indication that mutation, overexpression or rearrangement of an AKT family member gene has been detected in a sample.


SPANXB1 Positive

description: An indication that  SPANXB1 expression has been detected in a sample.


ISG15 Positive

description: An indication that expression of ISG15 has been detected in a sample.


Adrenal-Permissive HSD3B1 Genotype

description: A genetic finding indicating that a subject exhibits either homozygous or heterozygous expression of cytosine at position 1100 of the coding sequence of the HSD3B1 gene. This sequence encodes threonine at amino acid residue 367 of the 3 beta-hydroxysteroid dehydrogenase/Delta 5->4-isomerase type 1 protein (steroid Delta-isomerase) and is associated with decreased proteasomal degradation of steroid Delta-isomerase and an increased rate of conversion of dehydroepiandrosterone (DHEA) to androstenedione and more potent androgens, such as testosterone and dihydrotestosterone. Expression of this form of steroid Delta-isomerase may both affect progression of prostate and other hormone-responsive cancers and have an impact on therapeutic efficacy.


MAGEA4 Positive

description: An indication that MAGEA4 expression has been detected in a sample.


PI3K Alteration Positive

description: An indication that mutation, overexpression, fusion or rearrangement of a PI3K family member has been detected in a sample.


Philadelphia Chromosome Positive

description: Indicates that the Philadelphia chromosome abnormality, t(9;22)(q34;q11), has been detected in a sample.


Disseminated Tumor Cells Positive

description: An indication that single tumor cells or small clusters of tumor cells have been detected in a tissue sample.


PTEN Coding Region Mutation Present

description: A genetic finding indicating that a sample has one or more exon mutations in the PTEN gene.


Neoantigen-Positive

description: An indication that a unique neoantigen expression has been detected in the cancer samples of one or more patients.


name: MAPK Pathway Activating Gene Alteration Positive

description: An indication that gene alterations that result in activation of the MAPK signaling pathway have been detected. Causative gene alterations include mutations resulting in the expression of BRAF p.V600E and gene fusions involving FGFR2 or FGFR3.


IL2RB Positive

description: Indicates that IL2RB expression has been detected in a sample.


Cytomegalovirus DNA Positive

description: An indication that cytomegalovirus DNA has been detected in a sample.


Hepatitis C Virus Genotype 4 Positive

description: An indication that hepatitis C virus genotype 4 has been detected in a sample.


BCL6 Positive

description: An indication that B-cell lymphoma 6 expression has been detected in a sample.


CD7 Positive

description: An indication that expression of CD7 has been detected in a sample.


CD19 Positive

description: Indicates that CD19 expression has been detected in a sample.


name: Hepatitis B Virus Surface Antigen Positive

description: An indication that the hepatitis B virus surface protein antigen has been detected in a sample.


CD36 Positive

description: An indication that CD36 expression has been detected in a sample.


SCGB2A2 Positive

description: An indication that SCGB2A2 expression has been detected in a sample.


BRAF V600K Mutation Present

description: A molecular finding indicating the presence of a BRAF V600K mutation in a tissue sample.


Hepatitis B DNA Positive

description: An indication that hepatitis B DNA has been detected in a sample.


Hepatitis B Virus Positive

description: An indication that hepatitis virus B has been detected in a sample.


DSG3 Antibody Positive

description: An indication that antibodies that recognize desmoglein-3 (DSG3) have been detected in a sample.


Epstein-Barr Virus Positive

description: Indicates that Epstein-Barr virus has been detected in a sample.


NRAS Positive

description: An indication that NRAS expression has been detected in a sample.


CCND2 Positive

description: An indication that CCND2 expression has been detected in a sample.


FGFR4 Positive

description: An indication that FGFR4 expression has been detected in a sample.


FET/CREB Fusion-Positive

description: An indication that expression of the FET/CREB fusion has been detected in a sample.


CTLA4 Positive

description: An indication that CTLA4 expression has been detected in a sample.


HLA-A24 Positive Cells Present

description: A laboratory test result indicating the presence of HLA-A*24 positive cells in a tissue sample.


TFE3 Positive

description: Indicates that TFE3 expression has been detected in a sample.


CTAG2 Positive

description: Indicates that CTAG2 expression has been detected in a sample.


PVR Positive

description: An indication that PVR expression has been detected in a sample.


BST2 Positive

description: An indication that BST2 expression has been detected in a sample.


HTLV-1 Antibody Positive

description: An indication that antibodies that recognize the human T-cell lymphotropic virus 1 have been detected in a sample.


MAPK1 Fusion Positive

description: An indication that the expression of a MAPK1 fusion has been detected in a sample.


FGFR4 Gene Fusion Positive

description: An indication that a FGFR4 fusion gene has been detected in a sample.


p16 Positive by Immunohistochemistry

description: An indication that CDKN2A-p16 expression has been detected in a sample using immunohistochemical techniques.


KMT2A Gene Alteration Positive

description: An indication that mutation, overexpression, or rearrangement of the KMT2A gene has been detected in a sample.


UGT1A1 Polymorphism Positive

description: An indication that polymorphism of the UGT1A1 gene has been detected in a sample.


CD52 Positive

description: An indication that CD52 expression has been detected in a sample.


MITF Positive

description: An indication that MITF expression has been detected in a sample.


SLAMF7 Positive

description: An indication that SLAMF7 expression has been detected in a sample.


Heregulin Positive

description: Indicates that heregulin expression has been detected in a sample.


Strata Immune Signature Positive

description: An indication that a tumor sample subjected to the proprietary StrataNGS (next-generation sequencing) protocol has a molecular profile that may respond to treatment with an immunotherapeutic agent.


CD276 Antigen Positive

description: An indication that CD276 expression has been detected in a sample.


Somatostatin Receptor Positive

description: A laboratory test result indicating the presence or expression of somatostatin receptor in a sample.


Hepatitis C Virus RNA Positive

description: An indication that hepatitis C RNA has been detected in a sample.


HLA-B*44:02 Positive Cells Present

description: An indication that cells expressing HLA-B*44:02 have been detected in a sample.


CD38 Positive

description: An indication that CD38 expression has been detected in a sample.


NECTIN4 Positive

description: An indication that NECTIN4 expression has been detected in a sample.


name: MYC Gene Rearrangement and BCL6 Gene Rearrangement Positive

description: An indication that both rearrangements involving the MYC gene and rearrangements involving the BCL6 gene were detected in the same sample.


MDM2 Positive

description: An indication that MDM2 expression has been detected in a sample.


name: Activating RET Fusion Gene Mutation Positive

description: An indication that a fusion involving the RET gene that results in constitutive proto-oncogene tyrosine-protein kinase receptor Ret-dependent signal transduction and activation of downstream signaling pathways has been detected in a sample.


UGT1A1*1/*36 Positive

description: An indication that simultaneous expression of the *1 and *36 alleles of the UGT1A1 gene have been detected in a sample. This genotype is associated with extensive levels of metabolic activity against bilirubin and various pharmacologic agents.


Globo H Positive

description: An indication that the hexasaccharide glycosphingolipid and human cancer antigen globohexaosylceramide (Globo H) has been detected in a sample.


HLA-DRB1*03:01 Positive Cells Present

description: An indication that cells expressing HLA-DRB1*03:01 have been detected in a sample.


HLA-B*55:01 Positive Cells Present

description: An indication that cells expressing HLA-B*55:01 have been detected in a sample.


CD70 Positive

description: Indicates that CD70 expression has been detected in a sample.


UGT1A1*28/*37 Positive

description: An indication that simultaneous expression of the *28 and *37 alleles of the UGT1A1 gene have been detected in a sample. This genotype is associated with decreased levels of metabolic activity against bilirubin and various pharmacologic agents, which is associated with increased risk for drug toxicity.


CA19-9 Antigen Positive

description: An indication that expression of the carbohydrate antigen CA19-9 has been detected in a sample.


MPO Positive

description: An indication that expression of MPO has been detected in a sample.


MAPK Pathway Activated

description: A finding indicating that the MAPK signaling pathway is activated.


MAPK Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of a MAPK family gene has been detected in a sample.


name: SARS Coronavirus 2 Spike Glycoprotein N501Y Substitution Positive

description: An indication that expression of SARS coronavirus 2 spike glycoprotein where the asparagine at amino acid position 501 has been substituted with tyrosine has been detected in a sample.


ROS1 Fusion Positive

description: Indicates that the expression of a ROS1 fusion has been detected in a sample.


Monoclonal Band

description: Monoclonal immunoglobulin or monoclonal light chain that is present in the serum and/or urine. It is the result of a clonal B-cell or plasma cell proliferation.


Hepatitis C Virus Positive

description: Indicates that hepatitis C virus has been detected in a sample.


Human Herpesvirus 2 Positive

description: An indication that human herpesvirus 2 has been detected in a sample.


name: Activating RAF Family Alteration Positive

description: An indication that mislocalization, aggregation, mutation, overexpression, fusion or rearrangement that results in constitutive RAF family serine/threonine-protein kinase activity and aberrant activation of downstream signaling pathways has been detected in a sample.


BRCA1 Polymorphism Positive

description: An indication that polymorphism of the BRCA1 gene has been detected in a sample.


Human Herpesvirus 8 Positive

description: An indication that human herpesvirus 8 has been detected in a sample.


name: NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor

description: A finding indicating the presence of a NF1 mutation in a sample from a patient with malignant peripheral nerve sheath tumor.


Human Herpesvirus 1 DNA Positive

description: An indication that human herpesvirus 1 DNA has been detected in a sample.


Positive Lymph Node

description: The presence of metastatic cancer cells in a lymph node.


KEAP1 Alteration Positive

description: An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving KEAP1 has been detected in a sample.


IGF1 Positive

description: Indicates that IGF1 expression has been detected in a sample.


PAX5 Gene Alteration Positive

description: A finding indicating that mutation, underexpression, overexpression, amplification or rearrangement of the PAX5 gene has been detected in a sample.


CTLA4 Positive T-Lymphocytes

description: An indication that expression of CTLA4 has been detected in a sample comprised of T-lymphocytes.


SDH Complex Alteration Positive

description: An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving a either a member of or the entire SDH complex has been detected in a sample.


TCR Alpha-Beta Positive

description: An indication that expression of the heterodimeric complex comprised of the T-cell receptor (TCR) alpha and beta chain proteins has been detected in a sample.


NTRK1 Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the NTRK1 gene has been detected in a sample.


name: FGFR1 Tyrosine Kinase Domain Internal Tandem Duplication Positive

description: A genetic finding that refers to internal tandem duplications of sequences in the FGFR1 gene encoding the tyrosine kinase domain.


PTEN Gene Alteration Positive

description: An indication that mutation, overexpression, fusion or rearrangement involving the PTEN gene has been detected in a sample.


Merkel Cell Polyoma Virus Positive

description: A laboratory test result indicating the presence of the Merkel cell polyoma virus in a sample.


HLA-A3/A11 Positive Cells Present

description: A laboratory test result indicating that cells expressing HLA-A3 or HLA-A11 were detected in a sample.


Cytomegalovirus Positive

description: An indication that cytomegalovirus has been detected in a sample.


Anti-Poliovirus Antibody Positive

description: An indication that antibodies that recognize poliovirus have been detected in a sample.


ALK Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the ALK gene has been detected in a sample.


name: Phosphorylated Signal Transducer and Activator of Transcription 3 Positive

description: An indication that phosphorylated forms of the signal transducer and activator of transcription 3 protein have been detected in a sample.


Hormone Receptor Positive

description: A finding indicating that the neoplastic cells in a tissue sample test positive for hormone receptors.


Homozygous UGT1A1*37 Positive

description: An indication that homozygous expression of the UGT1A1*37 allele has been detected in a sample. This genotype is associated with decreased levels of metabolic activity against bilirubin and various pharmacologic agents, which is associated with increased risk for drug toxicity.


Ganglioside GD2 Positive

description: Indicates that expression of ganglioside GD2 has been detected in a sample.


Chromosome Deletion Detected

description: An indication that a chromosomal deletion was detected in a sample.


Chromogranin Positive

description: An indication that expression of one or more chromogranin family proteins has been detected in a sample.


name: Pediatric Glioma MYCN Molecular Signature Detected

description: An indication that the MYCN-type molecular signature for pediatric high grade glioma was detected in a sample. This signature occurs more frequently in supratentorial than infratentorial gliomas and co-occurs with expression of both wild-type histone H3 and wild-type IDH. The MYCN-type molecular signature is characterized by the following molecular abnormalities (in order of most to least frequent) TP53 gene mutations, MYCN gene amplification, gain of chromosome 7, loss of chromosome 10q, TERT promoter mutation, EGFR gene amplification and CDK4/6 mutations. This signature may rarely include MGMT promoter methylation, homozygous deletion of chromosome 9p. PDGFRA gene amplification and loss of ATRX protein expression.


TREM2 Positive

description: An indication that TREM2 expression has been detected in a sample.


PTK7 Positive

description: An indication that PTK7 expression has been detected in a sample.


RARA Positive

description: An indication that RARA expression has been detected in a sample.


name: Androgen Receptor Splice Variant 7 Positive

description: An indication that androgen receptor splice variant 3 expression has been detected in a sample.


ERBB3 Positive

description: An indication that expression of ERBB3 has been detected in a sample.


SMARCB1 Positive

description: An indication that expression of SMARCB1 has been detected in a sample.


CD2 Positive

description: An indication that CD2 expression has been detected in a sample.


MAP2K2 Fusion Positive

description: An indication that the expression of a MAP2K2 fusion has been detected in a sample.


HLA-C*08 Positive Cells Present

description: An indication that cells expressing HLA-C*08 have been detected in a sample.


HOXA10 Positive

description: An indication that expression of HOXA10 has been detected in a sample.


FGF Family Alteration Positive

description: Indicates that mutation, overexpression or rearrangement of an FGF family member has been detected in a sample.


ITGAD Positive

description: An indication that ITGAD expression has been detected in a sample.


NF1 Positive

description: An indication that expression of NF1 has been detected in a sample.


HLA-A11 Positive Cells Present

description: A laboratory test result indicating the presence of HLA-A11 positive cells in a tissue sample.


HLA-A31 Positive Cells Present

description: A laboratory test result indicating that cells expressing HLA-A31 were detected in a sample.


ASPH Positive

description: An indication that ASPH expression has been detected in a sample.


name: HER2/Neu Positive by Immunohistochemistry 31-40 Percent

description: An immunohistochemical staining finding indicating that 31-40 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.


MYB Gene Fusion Positive

description: An indication that a MYB fusion gene has been detected in a sample.


MET Fusion Gene Positive

description: An indication that a MET fusion gene has been detected in a sample.


KIR3DL2 Positive

description: An indication that expression of KIR3DL2 has been detected in a sample.


LY75 Positive

description: An indication that expression of LY75 has been detected in a sample.


Wnt Positive

description: Indicates that expression of one or more Wnt family members has been detected in a sample.


SIRPA V2/V2 Genotype Positive

description: An indication that homozygous expression of the SIRPA V2 allele has been detected in a sample.


cfDNA Mutation

description: A genetic finding indicating the presence of mutations in the cell-free DNA that is present in a peripheral blood sample.


MUC16 Ectodomain Antigen Positive

description: An indication that a soluble form of the extracellular domain of the mucin-16 protein has been detected in a sample. This is a marker for intramembrane cleavage of mucin-16.


name: HER2/Neu Positive by Immunohistochemistry 71-80 Percent

description: An immunohistochemical staining finding indicating that 71-80 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.


JC Virus Positive

description: An indication that JC virus has been detected in a sample.


KIT Positive

description: Indicates that KIT expression has been detected in a sample.


CD65 Positive

description: An indication that CD65 antigen expression has been detected in a sample.


name: Interleukin-3 Receptor Subunit Alpha Positive

description: Indicates that interleukin-3 receptor subunit alpha expression has been detected in a sample.


NTRK3 Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the NTRK3 gene has been detected in a sample.


TNFRSF18 Positive

description: An indication that TNFRSF18 expression has been detected in a sample.


NUP214 Gene Alteration Positive

description: A finding indicating that mutation, underexpression, overexpression, fusion or rearrangement involving the NUP214 gene has been detected in a sample.


HLA-A*0205 Positive Cells Present

description: An indication that cells expressing HLA-A*0205 have been detected in a sample.


SSX2 Positive

description: An indication that SSX2 expression has been detected in a sample.


Shared Neoantigen-Positive

description: An indication that a unique neoantigen expression has been detected in cancers diagnosed across a subset of patients.


SDHA Positive

description: An indication that expression of SDHA has been detected in a sample.


HLA-A1101 Positive Cells Present

description: A laboratory test result indicating the presence of HLA-A1101 positive cells in a tissue sample.


HLA-A2 Positive Cells Present

description: A laboratory test result indicating the presence of HLA-A*02 positive cells in a tissue sample.


HLA-C*0404 Positive Cells Present

description: An indication that cells expressing HLA-C*0404 have been detected in a sample.


Human Herpesvirus 6 Positive

description: An indication that human herpesvirus 6 has been detected in a sample.


BRAF V600E Mutation Present

description: A molecular finding indicating the presence of a BRAF V600E mutation in a tissue sample.


MET Gene Alteration Positive

description: An indication that mutation, overexpression, fusion or rearrangement involving the MET gene has been detected in a sample.


TRK Receptor Family Alteration Positive

description: Indicates that mutation, overexpression, or rearrangement of an TRK receptor family member has been detected in a sample.


HER2/Neu Positive

description: A laboratory test result indicating the presence of HER2/Neu in a tissue sample.


IGK Positive

description: An indication that IGK expression has been detected in a sample.


Aberrant HOXA Family Gene Expression

description: A finding indicating that aberrant activation of the expression of one or more HOXA family genes was detected in a sample.


name: MET/CEP7 Ratio Greater than or Equal to 4

description: An indication that the ratio of fluorescence in situ hybridization (FISH) signals for the MET gene versus the chromosome 7 centromere marker CEP7 is greater than or equal to 4. This result implies MET gene amplification is present.


BK Virus Positive

description: An indication that BK virus has been detected in a sample.


Cotinine Positive

description: An indication that cotinine has been detected in a sample.


ALK Positive

description: Indicates that ALK expression has been detected in a sample.


name: Xp11.2 Translocations/TFE3 Gene Fusions Present

description: A genetic finding indicating the presence of translocations involving the chromosome Xp11.2. These translocations result in the creation of gene fusions involving the TFE3 gene.


CD15 Positive

description: An indication that CD15 expression has been detected in a sample.


TNFRSF8 Positive

description: Indicates that TNFRSF8 expression has been detected in a sample.


Human Papillomavirus Positive

description: Indicates that human papillomavirus has been detected in a sample.


SPA17 Positive

description: An indication that SPA17 expression has been detected in a sample.


ANO1 Positive

description: An indication that expression of ANO1 has been detected in a sample.


Gene Amplification Positive

description: An indication that amplification of one or more genes of interest was detected in a sample.


Human Anti-Mouse Antibodies Positive

description: Indicates that human anti-mouse antibodies have been detected in a sample.


Coombs Test Positive

description: A laboratory test result demonstrating the presence of antibodies that act against red blood cells.


CD11c Positive

description: An indication that CD11c expression has been detected in a sample.


Biomarker Positive Malignant Neoplasm

description: A finding indicating the presence of a biomarker in a tumor sample from a patient with a malignant neoplasm.


FGFR2 Positive

description: An indication that FGFR2 expression has been detected in a sample.


CD57 Positive

description: Indicates that expression of the tumor antigen CD57 has been detected in a sample.


MPX Positive

description: An indication that at least one of the viral RNAs probed by the polymerase chain reaction-based cobas MPX test have been detected in a plasma or serum sample.


PDGFB Gene Fusion Positive

description: An indication that a PDGFB fusion gene has been detected in a sample.


Circulating Tumor-Derived DNA Positive

description: An indication that circulating tumor-derived DNA has been detected in a sample.


FGF3 Gene Fusion Positive

description: An indication that a FGF3 fusion gene has been detected in a sample.


DLL3 Gene Positive

description: An indication that the DLL3 gene has been detected in a sample.


Seropositive

description: A laboratory result which shows the presence of antibodies in the serum for the factor being tested.


Human Papillomavirus-33 Positive

description: An indication that human papillomavirus-33 has been detected in a sample.


ALK Fusion Gene Positive

description: An indication that an ALK fusion gene has been detected in a sample.


PDGFRB Gene Fusion Positive

description: An indication that a PDGFRB fusion gene has been detected in a sample.


Thyroglobulin Antibody Positive

description: An indication that antibodies that recognize thyroglobulin have been detected in a sample.


FOXO1 Fusion Positive

description: An indication that expression of a fusion containing sequences from FOXO1 has been detected in a sample.


PIK3CA Gene Alteration Positive

description: An indication that mutation, overexpression, fusion or rearrangement involving the PIK3CA gene has been detected in a sample.


THBD Positive

description: An indication that THBD expression has been detected in a sample.


MUC16 Positive

description: An indication that MUC16 expression has been detected in a sample.


ERBB Family Gene Fusion Positive

description: An indication that a fusion containing ERBB family gene sequences have been detected in a sample.


Positive Pelvic Lymph Node

description: A laboratory test result indicating the presence of a pathologic process in a pelvic lymph node.


Expression Positive

description: An indication that the expression of a gene, transcript or protein has been detected in a sample.


EDNRB Positive

description: An indication that EDNRB expression has been detected in a sample.


ERBB2 Fusion Positive

description: An indication that the expression of a fusion involving ERBB2 has been detected in a sample.


HRAS Positive

description: An indication that HRAS expression has been detected in a sample.


HLA-C*04:01 Positive Cells Present

description: An indication that cells expressing HLA-C*04:01 have been detected in a sample.


ICOS Positive

description: An indication that expression of ICOS has been detected in a sample.


LAGE-1A Positive

description: An indication that expression of the LAGE-1A isoform of the cancer/testis antigen 2 protein has been detected in a sample.


NTSR1 Positive

description: An indication that NTSR1 expression has been detected in a sample.


HLA-A*0202 Positive Cells Present

description: An indication that cells expressing HLA-A*0202 have been detected in a sample.


CXCL8 Positive

description: An indication that expression of CXCL8 has been detected in a sample.


HLA-A*26 Positive Cells Present

description: A laboratory test result indicating the presence of HLA-A*26 positive cells in a tissue sample.


AKT1 Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the AKT1 gene has been detected in a sample.


PAX5 Positive

description: An indication that PAX5 expression has been detected in a sample.


FGFR2 Gene Alteration Positive

description: An indication that mutation, overexpression, fusion or rearrangement involving the FGFR2 gene has been detected in a sample.


name: Metastasis Present in Distant Lymph Node

description: An indication that cancer cells have migrated from the primary tumor site and have been detected in one or more distant lymph nodes.


LAG3 Positive

description: An indication that LAG3 expression has been detected in a sample.


HLA-DRB1*04:04 Positive Cells Present

description: An indication that cells expressing HLA-DRB1*04:04 have been detected in a sample.


NPM1 Gene Alteration Positive

description: An indication that mutation (including nucleotide insertions or deletions), overexpression, or rearrangement of the NPM1 gene has been detected in a sample.


COL6A3 Positive

description: An indication that expression of COL6A3 has been detected in a sample.


MAPK3 Fusion Positive

description: An indication that the expression of a MAPK3 fusion has been detected in a sample.


CCND3 Positive

description: An indication that CCND3 expression has been detected in a sample.


TNFRSF9 Positive

description: An indication that TNFRSF9 expression has been detected in a sample.


HOXA9 Positive

description: An indication that expression of HOXA9 has been detected in a sample.


name: HER2/Neu Expression by Immunohistochemistry 3+

description: An immunohistochemical result of 3+ for HER2/Neu expression that is considered positive for expression.


C19MC Amplification

description: A genetic finding indicating the presence of amplification of the C19MC region on chromosome 19 (19q13.42).


Patient-Specific Neoantigen-Positive

description: An indication that neoantigen expression has been detected in the cancer sample of a specific patient.


name: HER2/Neu Positive by Immunohistochemistry 51-60 Percent

description: An immunohistochemical staining finding indicating that 51-60 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.


ACTA2 Positive

description: An indication that ACTA2 expression has been detected in a sample.


PDGFA Gene Fusion Positive

description: An indication that a PDGFA fusion gene has been detected in a sample.


HLA-B*35:08 Positive Cells Present

description: An indication that cells expressing HLA-B*35:08 have been detected in a sample.


TCR Gamma-Delta Positive

description: An indication that expression of the heterodimeric complex comprised of the T-cell receptor (TCR) gamma and delta chain proteins has been detected in a sample.


name: Monoclonal Myeloid or Lymphoid Cells Present

description: An indication that monoclonal myeloid or monoclonal lymphoid cells were detected in a sample.


HLA-C*01:02 Positive Cells Present

description: An indication that cells expressing HLA-C*01:02 have been detected in a sample.


CXCL13 Positive

description: An indication that expression of CXCL13 has been detected in a sample.


Mutation-Positive Lynch Syndrome

description: A finding of Lynch syndrome in which one is identified as a carrier or obligate carrier of a pathogenic mutation(s) in one of several DNA mismatch repair genes, including MLH1, MSH2/EPCAM, MSH6 or PMS2.


HA-2 Genotype Positive

description: A genetic finding indicating that a subject expresses the HA-2 genotype, which is defined as either homozygous or heterozygous expression of guanine at position 145 of the MYO1G gene, which encodes valine at amino acid residue 49 MYO1G(V). The MYO1G(V) form of unconventional myosin-Ig protein can be processed into a nonapeptide that can be presented by antigen expressing cells and recognized by HLA-A*0201 (HA-2+), while a variant MYO1G gene with adenine at position 145, which encodes a methionine at amino acid residue 49 (MYO1G(M)) does not produce a peptide that can be displayed by antigen presenting cells (HA-2-).


SLFN11 Positive

description: An indication that SLFN11 expression has been detected in a sample.


SLC39A6 Positive

description: An indication that SLC39A6 expression has been detected in a sample.


Androgen Receptor Positive

description: An indication that expression of androgen receptor has been detected in a sample.


GNRHR Positive

description: An indication that expression of GNRHR has been detected in a sample.


name: SARS Coronavirus 2 Spike Glycoprotein E484K Substitution Positive

description: An indication that expression of SARS coronavirus 2 spike glycoprotein where the glutamic acid at amino acid position 484 has been substituted with lysine has been detected in a sample.


WNT Pathway Activated

description: A finding indicating that the WNT signaling pathway is activated.


GRPR Positive

description: An indication that GRPR expression has been detected in a sample.


CEACAM6 Positive

description: An indication that CEACAM6 expression has been detected in a sample.


name: ABL Class Rearrangement Positive Ph-Like B Acute Lymphoblastic Leukemia

description: A finding indicating that activating rearrangements of an ABL class tyrosine kinase gene (which includes ABL1, ABL2, PDGFRB, and CSF1R) have been detected in a patient with Ph-like B acute lymphoblastic leukemia. This finding is associated with a higher relapse risk and may be amenable to treatment that utilizes tyrosine kinase inhibitors.


GPC3 Positive

description: An indication that GPC3 expression has been detected in a sample.


Human Papillomavirus-11 Positive

description: An indication that human papillomavirus-11 has been detected in a sample.


COX2 Positive

description: An indication that COX2 expression has been detected in a sample.


HLA-DRB1*04:01 Positive Cells Present

description: An indication that cells expressing HLA-DRB1*04:01 have been detected in a sample.


FLT3 Positive

description: An indication that FLT3 expression has been detected in a sample.


IL13RA2 Positive

description: An indication that IL13RA2 expression has been detected in a sample.


GPNMB Positive

description: An indication that GPNMB expression has been detected in a sample.


Rous Sarcoma Virus Positive

description: An indication that rous sarcoma virus has been detected in a sample.


CLDN18.2 Positive

description: An indication that expression of Claudin-18 Isoform A2 has been detected in a sample.


t(14;18) Positive

description: A cytogenetic finding indicating that the translocation (14;18) is present in cells.


FGFR3 Gene Fusion Positive

description: An indication that a FGFR3 fusion gene has been detected in a sample.


UGT1A1*36/*37 Positive

description: An indication that simultaneous expression of the *36 and *37 alleles of the UGT1A1 gene have been detected in a sample. This genotype is associated with intermediate levels of metabolic activity against bilirubin and various pharmacologic agents.


MAGEA12 Positive

description: An indication that MAGEA12 expression has been detected in a sample.


NUTM1 Positive

description: An indication that NUTM1 expression has been detected in a sample.


HLA-DRB1*15:01 Positive Cells Present

description: An indication that cells expressing HLA-DRB1*15:01 have been detected in a sample.


SARS Coronavirus 2 RNA Positive

description: An indication that SARS coronavirus 2 RNA has been detected in a sample.


RUNX1/RUNX1T1 Fusion Positive

description: Indicates that expression of the RUNX1/RUNXT1 fusion has been detected in a sample.


Bence Jones Protein Present

description: An indication that Bence Jones protein has been detected in a sample.


name: FLT3 Non-Internal Tandem Duplication Activating Mutation Positive

description: A genetic finding indicating that activating mutations in the FLT3 gene are detected in a sample but these are not internal tandem duplication mutations.


Helicobacter pylori Positive

description: An indication that Helicobacter pylori has been detected in a sample.


ARID1A Positive

description: An indication that ARID1A expression has been detected in a sample.


PAS Positive

description: An indication that a sample has detectable periodic acid-Schiff staining.


SETD2 Gene Alteration Positive

description: A finding indicating that mutation, amplification, deletion, or rearrangement involving the SETD2 gene has been detected in a sample.


Human Papillomavirus-6 Positive

description: Indicates that human papillomavirus-6 has been detected in a sample.


FOLH1 Positive

description: An indication that FOLH1 expression has been detected in a sample.


RET Positive

description: An indication that RET expression has been detected in a sample.


TP53 Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the TP53 gene has been detected in a sample.


CD1C Positive

description: An indication that CD1C expression has been detected in a sample.


Ganglioside GD2 Negative

description: An indication that expression of ganglioside GD2 has not been detected in a sample.


FGFR4 Alteration Positive

description: An indication that mutation, overexpression, fusion or rearrangement involving FGFR4 has been detected in a sample.


SPN Positive

description: An indication that expression of SPN has been detected in a sample.


Adenovirus Positive

description: An indication that adenovirus has been detected in a sample.


FH Alteration Positive

description: An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving FH has been detected in a sample.


Human Papillomavirus-35 Positive

description: An indication that human papillomavirus-35 has been detected in a sample.


KLRG1 Positive Lymphocyte

description: An indication that expression of KLRG1 has been detected in a cellular sample comprised of lymphocytes.


TP53 Positive

description: An indication that TP53 expression has been detected in a sample.


RET Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the RET gene has been detected in a sample.


Persistent SARS Coronavirus 2 Positive

description: An indication that SARS-CoV-2 continued to be detected in a patient's biological samples beyond the presumptive infectious period of acute COVID-19.


SLCO1B3 Gene Positive

description: An indication that the SLCO1B3 gene has been detected in a sample.


FCER2 Positive

description: Indicates that FCER2 expression has been detected in a sample.


MAGEA1 Positive

description: An indication that expression of MAGEA1 has been detected in a sample.


name: HER2/Neu Positive by Immunohistochemistry 81-90 Percent

description: An immunohistochemical staining finding indicating that 81-90 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.


HLA-DP4 Positive Cells Present

description: An indication that the expression of major histocompatibility complex, class II DP protein in which haplotype of the alpha subunit is HLA-DPA1*0103 and haplotype of the beta subunit is either HLA-DPB1*0401 or HLA-DPB1*0402 allele of the HLA-DPB1 gene is present in a cell or tissue sample.


Epstein-Barr Virus DNA Positive

description: An indication that Epstein-Barr virus DNA has been detected in a sample.


FGF19 Positive

description: An indication that FGF19 expression has been detected in a sample.


CD20 Positive

description: A finding indicating that CD20 is present on cells or expressed by cells.


MLANA Positive

description: An indication that MLANA expression has been detected in a sample.


SELE Positive

description: An indication that expression of SELE has been detected in a sample.


IRF4 Positive

description: An indication that expression of IRF4 has been detected in a sample.


MECOM Positive

description: An indication that expression of MECOM has been detected in a sample.


name: Homologous Recombination Repair Gene Alteration Positive

description: An indication that mutation, overexpression, or rearrangement of a gene involved in homologous recombination repair of DNA has been detected in a sample.


Tetrahydrocannabinol Positive

description: An indication that tetrahydrocannabinols, metabolites of cannabis (marijuana) and hemp, have been detected in a sample.


CD28 Positive

description: An indication that expression of CD28 has been detected in a sample.


HLA-B*07 Positive Cells Present

description: An indication that cells expressing HLA-B*07 have been detected in a sample.


TACSTD2 Positive

description: An indication that TACSTD2 expression has been detected in a sample.


DNTT Positive

description: An indication that DNTT expression has been detected in a sample.


CD8 Positive

description: Indicates that expression of the CD8 complex has been detected in a sample.


name: Merkel Cell Polyomavirus T Antigen Positive

description: An indication that the expression of the Merkel cell polyomavirus T antigen has been detected in a sample.


name: HER2/Neu Positive by Immunohistochemistry Less than 1 Percent

description: An immunohistochemical staining finding indicating that less than 1 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.


Distal GATA2 Enhancer Repositioning

description: A finding indicating the repositioning of a distal GATA2 enhancer caused by chromosomal rearrangements.


Four or More Positive Lymph Nodes

description: An indication that cancer cells have been detected in four or more lymph nodes.


Genetic Fusion Positive

description: An indication that a genetic fusion was detected in a sample.


SOX11 Positive

description: An indication that SOX11 expression has been detected in a sample.


HLA-B*13:02 Positive Cells Present

description: An indication that cells expressing HLA-B*13:02 have been detected in a sample.


name: EZH2 Gene Copy Number Alteration Positive

description: A genetic finding indicating that the number of copies of the EZH2 gene in a samples is either increased (amplified) or decreased (deleted) from the normal copy number (2).


name: EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma

description: A finding indicating the presence of the epidermal growth factor receptor T790M amino acid substitution mutation in a tumor sample from a patient with non-small cell lung carcinoma.


HLA-A3 Positive Cells Present

description: A laboratory test result indicating the presence of HLA-A*03 positive cells in a tissue sample.


HTLV-1 Positive

description: An indication that HTLV-1 was detected in a sample.


Influenza A Virus Positive

description: An indication that influenza A virus has been detected in a sample.


Sonic Hedgehog/Patch Pathway Activated

description: A finding indicating that the sonic hedgehog/patch pathway is activated.


PDCD1 Positive

description: An indication that expression of PDCD1 has been detected in a sample.


HLA-A1 Positive Cells Present

description: A laboratory test result indicating the presence of HLA-A*01 positive cells in a tissue sample.


HLA-B*5103 Positive Cells Present

description: An indication that cells expressing HLA-B*5103 have been detected in a sample.


name: Monoclonal Hematopoietic Stem and Progenitor Cells Present

description: A finding indicating the presence of a monoclonal population of hematopoietic stem and progenitor cells in a tissue sample.


EGFRvIII Positive

description: An indication that expression of EGFRvIII has been detected in a sample.


Adrenal-Restrictive HSD3B1 Genotype

description: A genetic finding indicating that a subject exhibits homozygous expression of adenine at position 1100 of the coding sequence of the HSD3B1 gene. This sequence encodes asparagine at amino acid residue 367 of the 3 beta-hydroxysteroid dehydrogenase/Delta 5->4-isomerase type 1 protein (steroid Delta-isomerase) and is associated with increased proteasomal degradation of steroid Delta-isomerase and a decreased rate of conversion of dehydroepiandrosterone (DHEA) to androstenedione. Expression of this form of steroid Delta-isomerase may both affect the progression of prostate and other hormone-responsive cancers and have an impact on therapeutic efficacy.


FAP Positive

description: An indication that FAP expression has been detected in a sample.


AKT3 Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the AKT3 gene has been detected in a sample.


CD34 Positive

description: An indication that CD34 expression has been detected in a sample.


SHH Positive

description: An indication that SHH expression has been detected in a sample.


Latent Membrane Protein 1 Positive

description: Indicates that Epstein-Barr virus latent membrane protein 1 expression has been detected in a sample.


description: A finding indicating that an individual has a human leukocyte antigen (HLA) genotype profile that includes expression of HLA-DRB1*15:01, HLA-DQA1*01:02 and HLA-DQB1*06:02.


name: Activating RAF Family Fusion Gene Positive

description: An indication that a fusion containing RAF family gene sequences that results in aberrant activation of both RAF family serine/threonine-protein kinase activity and their downstream signaling pathways has been detected in a sample


XK Positive

description: An indication that XK expression has been detected in a sample.


FCGR1A Positive

description: An indication that FCGR1A expression has been detected in a sample.


RELA Fusion Positive

description: An indication that expression of a fusion containing sequences from RELA has been detected in a sample.


name: Latent Nuclear Antigen Antibody Positive

description: An indication that antibodies that recognize the human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) latent nuclear antigen protein have been detected in a sample.


PRLR Positive

description: An indication that PRLR expression has been detected in a sample.


Clostridium difficile Positive

description: An indication that Clostridium difficile was detected in a sample.


CDH3 Positive

description: Indicates that CDH3 expression has been detected in a sample.


CCND1 Positive

description: Indicates that CCND1 expression has been detected in a sample.


name: SARS Coronavirus 2 IgM Antibody Positive

description: An indication that antibodies of the IgM class that recognize SARS coronavirus 2 have been detected in a sample.


HLA-B*1501 Positive Cells Present

description: An indication that cells expressing HLA-B*1501 have been detected in a sample.


PTEN Alteration Positive

description: An indication that mutation, overexpression, fusion or rearrangement involving PTEN has been detected in a sample.


HLA-DPB1*04 Positive Cells Present

description: A laboratory test result indicating that cells expressing HLA-DPB1*04 were detected in a sample.


RSPO2 Gene Fusion Positive

description: An indication that the expression of a fusion containing sequences from the RSPO2 gene has been detected in a sample.


Homozygous UGT1A1*28 Positive

description: An indication that homozygous expression of the UGT1A1*28 allele has been detected in a sample.


MYCN Positive

description: Indicates that MYCN expression has been detected in a sample.


HER2/Neu Positive by FISH

description: A laboratory test result indicating the presence of HER2/Neu in a tissue sample using fluorescence in situ hybridization.


ERBB3 Fusion Positive

description: An indication that the expression of a fusion involving ERBB3 has been detected in a sample.


PDGFRA Gene Fusion Positive

description: An indication that a PDGFRA fusion gene has been detected in a sample.


Hepatitis C Virus Antibody Positive

description: An indication that antibodies that recognize the hepatitis C virus have been detected in a sample.


MYBL1 Gene Fusion Positive

description: An indication that a MYBL1 fusion gene has been detected in a sample.


name: Translocations Involving Tyrosine Kinases or Cytokine Receptors Present

description: A cytogenetic finding indicating the presence of translocations involving either tyrosine kinases or cytokine receptors.


JAK3 Fusion Positive

description: Indicates that expression of a fusion containing sequences from JAK3 has been detected in a sample.


Positive Para-Aortic Lymph Node

description: A laboratory test result indicating the presence of a pathologic process in a para-aortic lymph node.


TRK Receptor Family Fusion Positive

description: Indicates that the expression of a fusion involving a TRK receptor family member has been detected in a sample.


name: HER2/Neu Positive by Immunohistochemistry 11-20 Percent

description: An immunohistochemical staining finding indicating that 11-20 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.


RAF1 Fusion Positive

description: An indication that the expression of a fusion involving RAF1 has been detected in a sample.


ROPN1 Positive

description: An indication that ROPN1 expression has been detected in a sample.


CD79A Positive

description: An indication that CD79A expression has been detected in a sample.


IGF1R Positive

description: Indicates that IGF1R expression has been detected in a sample.


GUCY2C Positive

description: Indicates that GUCY2C expression has been detected in a sample.


IGHV4-34 Positive

description: An indication that IGHV4-34 expression has been detected in a sample.


MAP2K1 Fusion Positive

description: An indication that the expression of a MAP2K1 fusion has been detected in a sample.


Anal High Risk HPV DNA Positive

description: An indication that DNA from a high risk, oncogenic human papillomavirus serotype, most commonly 16, 18, 31, has been detected in a sample from the anus.


Human Papillomavirus-16 Positive

description: Indicates that human papillomavirus-16 has been detected in a sample.


HLA-DPB1*0401 Positive Cells Present

description: An indication that cells expressing HLA-DPB1*0401 have been detected in a sample.


SARS Coronavirus 2 Positive

description: An indication that SARS coronavirus 2 has been detected in a sample.


HLA-DRB1*11:04 Positive Cells Present

description: An indication that cells expressing HLA-DRB1*11:04 have been detected in a sample.


EPOR Fusion Positive

description: An indication that expression of a fusion containing sequences from EPOR has been detected in a sample.


name: FLT3 Internal Tandem Duplication Positive

description: An indication that internal tandem duplication within the FLT3 gene has been detected in a sample.


BRAF Fusion Positive

description: An indication that BRAF fusion expression has been detected in a sample.


Rearrangement Detected

description: An indication that a cytogenetic rearrangement was detected in a sample.


HLA-A*0201 HA-1 Positive Cells Present

description: An indication that cells that are expressing the peptide/major histocompatibility protein complex (pMHC) comprised of a minor histocompatibility peptide antigen (HA-1) bound to HLA-A*0201 are present in a sample.


Human Papillomavirus-31 Positive

description: An indication that human papillomavirus-31 has been detected in a sample.


Hepatitis B Antigen Positive

description: An indication that hepatitis B antigens have been detected in a sample.


BAP1 Loss of Function Mutation Positive

description: An indication that expression of BAP1 with a loss of function mutation has been detected in a sample.


Nonclonal Cellular Population Present

description: An indication that the cells in a sample did not arise from a single progenitor cell.


Cancer Antigen 72-4 Positive

description: An indication that expression of cancer antigen 72-4 has been detected in a sample.


VTCN1 Positive

description: An indication that VTCN1 expression has been detected in a sample.


KRAS Positive

description: An indication that KRAS expression has been detected in a sample.


Human Herpesvirus 1 Positive

description: An indication that human herpesvirus 1 has been detected in a sample.


NUP98 Gene Alteration Positive

description: A finding indicating that mutation, underexpression, overexpression, fusion or rearrangement involving the NUP98 gene has been detected in a sample.


name: SARS Coronavirus 2 Spike Glycoprotein D614G Substitution Positive

description: An indication that expression of SARS coronavirus 2 spike glycoprotein where the aspartic acid at amino acid position 614 has been substituted with glycine has been detected in a sample.


RSPO3 Gene Fusion Positive

description: An indication that the expression of a fusion containing sequences from the RSPO3 gene has been detected in a sample.


Influenza B Virus Positive

description: An indication that influenza B virus has been detected in a sample.


Non-KMT2A MLLT10 Rearrangement Positive

description: An indication that a cytogenetic rearrangement involving MLLT10 but not involving KMT2A was detected in a sample.


CEACAM5 Positive

description: An indication that CEACAM5 expression has been detected in a sample.


PMEL Positive

description: An indication that expression of PMEL has been detected in a sample.


BCOR Genetic Alteration

description: An alteration in the BCOR gene that results in the creation of BCOR-related gene fusions or BCOR internal tandem duplication (BCOR-ITD).


FGFR Gene Fusion Positive

description: Indicates that a fusion containing FGFR family gene sequences has been detected in a sample.


AKT2 Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the AKT2 gene has been detected in a sample.


name: SARS Coronavirus 2 Spike Glycoprotein 69/70 Deletion Positive

description: An indication that expression of SARS coronavirus 2 spike glycoprotein where the amino acids at positions 69 and 70 have been deleted has been detected in a sample.


FGFR1 Gene Fusion Positive

description: An indication that a FGFR1 fusion gene has been detected in a sample.


HLA-DR Positive

description: An indication that expression of an HLA-DR antigen has been detected in a sample.


ENPP3 Positive

description: An indication that ENPP3 expression has been detected in a sample.


ROR1 Positive

description: An indication that ROR1 expression has been detected in a sample.


FGFR2 Fusion Positive

description: An indication that expression of a fusion containing sequences from FGFR2 has been detected in a sample.


FGFR1 Gene Alteration Positive

description: An indication that mutation, overexpression, fusion or rearrangement involving the FGFR1 gene has been detected in a sample.


CDKN2A-p16 Positive

description: Indicates that CDKN2A-p16 expression has been detected in a sample.


BCL2 Positive

description: An indication that BCL2 expression has been detected in a sample.


HLA-C*07:02 Positive Cells Present

description: A laboratory test result indicating that cells expressing HLA-C*07:02 were detected in a sample.


Epstein-Barr Virus Early RNA Positive

description: Indicates that Epstein-Barr virus early RNA has been detected in a sample.


Phosphorylated Histone H3 Positive

description: An indication that phosphorylated forms of histone H3 protein have been detected in a sample.


name: Monoclonal Hepatocyte Population Present

description: A finding indicating that monoclonal hepatocytes were detected in a sample.


ERBB3 Gene Fusion Positive

description: An indication that an ERBB3 fusion gene has been detected in a sample.


name: HER2/Neu Positive by Immunohistochemistry 41-50 Percent

description: An immunohistochemical staining finding indicating that 41-50 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.


name: RAS Signal Transduction Pathway Activated

description: An indication that activation of the RAS signal transduction pathway has been detected in a sample.


name: Tartrate Resistant Acid Phosphatase Positive Cells Present

description: An indication that cells expressing tartrate resistant acid phosphatase (TRAP) have been detected in a sample.


KEAP1 Gene Alteration Positive

description: An indication that underexpression, overexpression, mutation, amplification, fusion or rearrangement involving the KEAP1 gene has been detected in a sample.


MYD88 Fusion Positive

description: Indicates that expression of a fusion containing sequences from MYD88 has been detected in a sample.


Epstein-Barr Virus Antibody Positive

description: An indication that antibodies that recognize the Epstein-Barr virus have been detected in a sample.


MAGEC1 Positive

description: An indication that MAGEC1 expression has been detected in a sample.


UGT1A1*6/*28 Positive

description: An indication that simultaneous expression of the *6 and *28 alleles of the UGT1A1 gene have been detected in a sample.


Cytoplasmic CD3 Positive

description: An indication that cytoplasmic expression of the CD3 complex has been detected in a sample.


F3 Positive

description: An indication that expression of F3 has been detected in a sample.


CD27 Positive

description: An indication that CD27 expression has been detected in a sample.


CD14 Positive

description: An indication that CD14 expression has been detected in a sample.


Human Anti-Chimeric Antibody Positive

description: An indication that antibodies directed against chimeric therapeutic antibodies have been detected in a human sample.


IL1RL1 Positive

description: An indication that IL1RL1 expression has been detected in a sample.


MAGEA3 Positive

description: An indication that melanoma-associated antigen 3 expression has been detected in a sample.


S100B Positive

description: An indication that expression of S100B has been detected in a sample.


SDHB Positive

description: An indication that SDHB expression has been detected in a sample.


CCR5 Positive

description: An indication that CCR5 expression has been detected in a sample.


HLA Phenotype Positive

description: An indication that a subject's human leukocyte antigen (HLA) complex expression profile is appropriate for inclusion in a study.


RET Fusion Positive

description: Indicates that the expression of a RET fusion has been detected in a sample.


Positive Herpes Simplex Virus Culture

description: Laboratory test results demonstrating the presence of the Herpes Simplex virus in a specimen.


DLL3 Positive

description: An indication that DLL3 expression has been detected in a sample.


KMT2A Fusion Positive

description: Indicates that the expression of a KMT2A fusion has been detected in a sample.


Hepatitis B Surface Antibody Positive

description: An indication that antibodies that recognize a hepatitis B virus surface protein have been detected in a sample.


VHL Alteration Positive

description: An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving VHL has been detected in a sample.


PDCD1 Positive T-Lymphocytes

description: An indication that expression of PDCD1 has been detected in a sample comprised of T-lymphocytes.


PRAME Positive

description: An indication that PRAME expression has been detected in a sample.


SBB Positive

description: An indication that a sample has detectable Sudan black B staining.


Sensitizing ROS1 Fusion Positive

description: An indication that expression of ROS1 fusion containing a ROS1 alteration that causes increased sensitivity to ROS1 inhibitory agents has been detected in a sample.


PTEN Positive

description: An indication that PTEN expression has been detected in a sample.


name: FLT3-Internal Tandem Duplication High Allelic Ratio

description: A molecular genetic finding in acute myeloid leukemias indicating that FLT3-internal tandem duplication (FLT3-ITD) is the dominant lesion, and which is present in the majority or all of the leukemic cells.


name: MYC Gene Rearrangement, BCL2 Gene Rearrangement, and BCL6 Gene Rearrangement Positive

description: An indication that all three rearrangements involving the MYC gene, BCL2 gene, and BCL6 gene were detected in the same sample.


Estrogen Receptor Positive

description: An indication that estrogen receptor alpha expression has been detected in a sample.


name: HER2/Neu Positive by Immunohistochemistry 91-100 Percent

description: An immunohistochemical staining finding indicating that 91-100 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.


Respiratory Syncytial Virus Positive

description: An indication that respiratory syncytial virus has been detected in a sample.


SLC5A5 Positive

description: An indication that SLC5A5 expression has been detected in a sample.


TYK2 Fusion Positive

description: An indication that expression of a fusion containing sequences from TYK2 has been detected in a sample.


Positive Blood Culture

description: A laboratory test result demonstrating the presence of a specific organism in a blood sample after culture.


MCPyV Positive

description: An indication that Merkel cell polyomavirus has been detected in a sample.


ESR2 Positive

description: An indication that expression of ESR2 has been detected in a sample.


Positive Pseudomonas Culture

description: A laboratory test result demonstrating the presence of bacteria from the genus Pseudomonas in a sample after culture.


NCAM1 Positive

description: Indicates that NCAM1 expression has been detected in a sample.


HLA-A*0207 Positive Cells Present

description: An indication that cells expressing HLA-A*0207 have been detected in a sample.


C3d Positive

description: An indication that C3d expression has been detected in a sample.


MAGEA10 Positive

description: An indication that melanoma-associated antigen 10 expression has been detected in a sample.


KIR2DL1 Polymorphism Positive

description: An indication that polymorphism of the KIR2DL1 gene has been detected in a sample.


CKB Positive

description: An indication that CKB expression has been detected in a sample.


STEAP1 Positive

description: Indicates that STEAP1 expression has been detected in a sample.


Anti-HLA Class I Antibody Positive

description: An indication that antibodies that recognize HLA Class I protein antigens have been detected in a sample.


name: Laboratory-Confirmed Human Monkeypox Infection

description: An indication that a laboratory test has confirmed that a human subject has a human monkeypox infection.


name: HER2/Neu Positive by Immunohistochemistry

description: An immunohistochemical staining finding indicating that cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.


CD37 Positive

description: An indication that CD37 expression has been detected in a sample.


NR3C1 Positive

description: Indicates that NR3C1 expression has been detected in a sample.


SLC6A8 Positive

description: An indication that expression of SLC6A8 has been detected in a sample.


ALCAM Positive

description: An indication that expression of ALCAM has been detected in a sample.


Transcript Variant Positive

description: An indication that variant transcripts were detected in a sample.


ERBB2 Gene Fusion Positive

description: An indication that an ERBB2 fusion gene has been detected in a sample.


MKI67 Positive

description: An indication that MKI67 expression has been detected in a sample.


PDE3A Positive

description: An indication that PDE3A expression has been detected in a sample.


name: Pediatric Glioma RTK2 Molecular Signature Detected

description: An indication that the RTK2-type molecular signature for pediatric high grade glioma was detected in a sample. This signature occurs more frequently in supratentorial than infratentorial gliomas and co-occurs with expression of both wild-type histone H3 and wild-type IDH. The RTK2-type molecular signature is characterized by the following molecular abnormalities (in order of most to least frequent) homozygous deletion of chromosome 9p, TERT promoter mutation, EGFR gene amplification, TP53 gene mutation, loss of chromosome 10q, gain of chromosome 7 and CDK4/6 mutations. This signature may rarely include MYCN gene amplification and PDGFRA gene amplification. Additionally, MGMT promoter methylation and loss of ATRX protein expression are not characteristics of this signature.


ROS1 Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the ROS1 gene has been detected in a sample.


name: EGFR Signaling Pathway Alteration Positive

description: An indication that a sample displays an alteration in the progression of the EGFR signaling pathway.


name: MYC Gene Rearrangement and BCL2 Gene Rearrangement Positive

description: An indication that both rearrangements involving the MYC gene and rearrangements involving the BCL2 gene were detected in the same sample.


JAK2 Fusion Positive

description: Indicates that expression of a fusion containing sequences from JAK2 has been detected in a sample.


HTLV Positive

description: An indication that HTLV was detected in a sample.


name: HER2/Neu Positive by Immunohistochemistry 1-10 Percent

description: An immunohistochemical staining finding indicating that 1-10 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.


NPM1 Gene Fusion Positive

description: An indication that the expression of a fusion containing sequences derived from the NPM1 gene has been detected in a sample.


NTRK1 Fusion Positive

description: Indicates that the expression of a NTRK1 fusion has been detected in a sample.


PML/RARA Fusion Positive

description: Indicates that expression of the PML/RARA fusion has been detected in a sample.


HLA-A*0201 Positive Cells Present

description: A laboratory test result indicating the presence of HLA-A*0201 positive cells in a tissue sample.


TYRP1 Positive

description: An indication that expression of TYRP1 has been detected in a sample.


CD44 Positive

description: An indication that CD44 expression has been detected in a sample.


CTAG1B Positive

description: An indication that CTAG1B expression has been detected in a sample.


BRCA2 Polymorphism Positive

description: An indication that polymorphism of the BRCA2 gene has been detected in a sample.


NTRK2 Fusion Positive

description: Indicates that the expression of a NTRK2 fusion has been detected in a sample.


Homozygous UGT1A1*36 Positive

description: An indication that homozygous expression of the UGT1A1*36 allele has been detected in a sample. This genotype is associated with extensive levels of metabolic activity against bilirubin and various pharmacologic agents.


CD5 Positive

description: Indicates that CD5 expression has been detected in a sample.


Monoclonal Eosinophils Present

description: A finding indicating that monoclonal eosinophils were detected in a sample.


ROS1 Fusion Gene Positive

description: An indication that a ROS1 fusion gene has been detected in a sample.


HLA-B*4601 Positive Cells Present

description: An indication that cells expressing HLA-B*4601 have been detected in a sample.


ENO2 Positive

description: An indication that ENO2 expression has been detected in a sample.


Biallelic Mutation Positive

description: An indication that a mutation has been detected in both alleles of a single gene.


Paraneoplastic Antibody Positive

description: An indication that autoantibodies that recognize paraneoplastic antigens have been detected in a sample.


MLL Positive

description: An indication that MLL expression has been detected in a sample.


One or More Positive Axillary Nodes

description: Presence of one or more lymph nodes in the area of the armpit in which cancerous cells have been detected.


SLC45A2 Positive

description: An indication that SLC45A2 expression has been detected in a sample.


Wnt Family Gene Alteration Positive

description: An indication that mutation, overexpression, or rearrangement of an Wnt gene family member has been detected in a sample.


EGFR Gene Alteration Positive

description: A finding indicating that mutation, overexpression or rearrangement of the EGFR gene has been detected in a sample.


EPHA5 Positive

description: An indication that expression of EPHA5 has been detected in a sample.


CT83 Positive

description: An indication that expression of CT83 has been detected in a sample.


FGFR2 Gene Fusion Positive

description: An indication that a FGFR2 fusion gene has been detected in a sample.


CD4 Positive

description: An indication that CD4 expression has been detected in a sample.


HLA-A*24:02 Positive Cells Present

description: A laboratory test result indicating the presence of HLA-A*24:02 positive cells in a tissue sample.


Carcinoembryonic Antigen Positive

description: A laboratory test result indicating the presence of carcinoembryonic antigen in a sample.


Progesterone Receptor Positive

description: An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.


Tyrosinase Positive

description: Indicates that tyrosinase expression has been detected in a sample.


CYP3A5 Polymorphism Positive

description: An indication that polymorphism of the CYP3A5 gene has been detected in a sample.


Homozygous UGT1A1*6 Positive

description: An indication that homozygous expression of the UGT1A1*6 allele has been detected in a sample.


ALDH2*1/*2 Genotype Positive

description: An indication that simultaneous expression of the wild-type (ALDH2*1) and loss of function (ALDH2*2) alleles of the ADLH2 gene have been detected in a sample.


HTLV-2 Positive

description: An indication that HTLV-2 was detected in a sample.


EWSR1 Fusion Positive

description: An indication that a EWSR1 fusion has been detected in a sample.


Survivin Positive

description: An indication that survivin expression has been detected in a sample.


GLI1 Positive

description: An indication that GLI1 expression has been detected in a sample.


One to Three Positive Lymph Nodes

description: An indication that cancer cells have been detected in one, two or three lymph nodes.


Traumatic Tap

description: Contamination of a cerebrospinal fluid sample by red blood cells greater than 10/mm3.


EWSR1/WT1 Fusion Positive

description: An indication that expression of the EWSR1/WT1 fusion has been detected in a sample.


HLA-DRB1*13:03 Positive Cells Present

description: An indication that cells expressing HLA-DRB1*13:03 have been detected in a sample.


An androstanoid that is testosterone substituted at C2  by a hydroxy group with undefined stereochemistry.


An androstanoid that is testosterone carrying an additional hydroxy substituent at the 2beta-position.


An oligosaccharide sulfate consisting of 3-O-sulfo-beta-D-galactopyranose and -2-acetamido-2-deoxy-D-glucopyranose residues joined by a (1->4) glycosidic bond.


laminarabiose

A glycosylglucose consisting of D-glucose with undefined anomeric stereochemistry and a beta-D-glucosyl residue attached at the 3-position.


A laminarabiose having beta-configuration at the reducing end anomeric centre.


A glycotriaosylceramide having N-propionyl-beta-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosyl as the triaosyl component.


A glycotetraosylceramide having beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucose as the tetrasaccharide component.


A glycotetraosylceramide having a beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc component attached to the primary hydroxy function of a ceramide with undefined sphingoid base and fatty acyl chain.


name: 4-[[(4-methoxyanilino)-oxomethyl]amino]benzoic acid methyl ester


name: Appendix Neuroendocrine Tumor pM1a TNM Finding v8

description: Appendix neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)


A 1,2-diacyl-3-alpha-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are both oleoyl.


A ketoaldehyde that is pentanal substituted by an oxo group at position 4.


Retinoblastoma cT3b TNM Finding v8

description: Tumor invasion of choroid, pars plana, ciliary body, lens, zonules, iris, or anterior chamber. (from AJCC 8th Ed.)


Retinoblastoma Clinical TNM Finding v8

description: A clinical finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system.


name: Retinoblastoma Clinical Primary Tumor TNM Finding v8

description: A clinical finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. Each eye is scored for cT criteria, and the cT category for the patient is based on the most advanced eye. (from AJCC 8th Ed.)


Retinoblastoma cM1a TNM Finding v8

description: Retinoblastoma with tumor(s) involving any distant site (e.g., bone marrow, liver) on clinical or radiologic tests. (from AJCC 8th Ed.)


Retinoblastoma cT2b TNM Finding v8

description: Vitreous seeding and/or subretinal seeding. (from AJCC 8th Ed.)


Retinoblastoma cT4a TNM Finding v8

description: Radiologic evidence of retrobulbar optic nerve involvement or thickening of optic nerve or involvement of orbital tissues. (from AJCC 8th Ed.)


Retinoblastoma cT4b TNM Finding v8

description: Extraocular tumor clinically evident with proptosis and/or an orbital mass. (from AJCC 8th Ed.)


Retinoblastoma cN0 TNM Finding v8

description: Retinoblastoma with no regional lymph node involvement. (from AJCC 8th Ed.)


Retinoblastoma cM1b TNM Finding v8

description: Retinoblastoma with tumor involving the CNS on radiologic imaging (not including trilateral retinoblastoma). (from AJCC 8th Ed.)


Retinoblastoma cNX TNM Finding v8

description: Retinoblastoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)


name: Retinoblastoma Clinical Regional Lymph Nodes TNM Finding v8

description: A clinical finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.


Retinoblastoma cT3c TNM Finding v8

description: Raised intraocular pressure with neovascularization and/or buphthalmos. (from AJCC 8th Ed.)


Retinoblastoma cN1 TNM Finding v8

description: Retinoblastoma with evidence of preauricular, submandibular, and cervical lymph node involvement. (from AJCC 8th Ed.)


name: Retinoblastoma Clinical Distant Metastasis TNM Finding v8

description: A clinical finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.


Retinoblastoma cT3e TNM Finding v8

description: Aseptic orbital cellulitis. (from AJCC 8th Ed.)


Retinoblastoma cT3a TNM Finding v8

description: Phthisis or pre-phthisis bulbi. (from AJCC 8th Ed.)


Retinoblastoma cT4 TNM Finding v8

description: Extraocular tumor(s) involving orbit, including optic nerve. (from AJCC 8th Ed.)


Retinoblastoma cT1a TNM Finding v8

description: Tumors 3 mm or less and further than 1.5 mm from disc and fovea. (from AJCC 8th Ed.)


Retinoblastoma cTX TNM Finding v8

description: Unknown evidence of intraocular tumor. (from AJCC 8th Ed.)


Retinoblastoma cT3 TNM Finding v8

description: Advanced intraocular tumor(s). (from AJCC 8th Ed.)


Retinoblastoma cT2 TNM Finding v8

description: Intraocular tumor(s) with retinal detachment, vitreous seeding, or subretinal seeding. (from AJCC 8th Ed.)


Retinoblastoma cM1 TNM Finding v8

description: Retinoblastoma with distant metastasis without microscopic confirmation. (from AJCC 8th Ed.)


Retinoblastoma cT1 TNM Finding v8

description: Intraretinal tumor(s) with subretinal fluid 5 mm or less from the base of any tumor. (from AJCC 8th Ed.)


Retinoblastoma cT2a TNM Finding v8

description: Subretinal fluid more than 5 mm from the base of any tumor. (from AJCC 8th Ed.)


Retinoblastoma cT0 TNM Finding v8

description: No evidence of intraocular tumor. (from AJCC 8th Ed.)


Retinoblastoma cM0 TNM Finding v8

description: Retinoblastoma with no signs or symptoms of intracranial or distant metastasis. (from AJCC 8th Ed.)


Retinoblastoma cT3d TNM Finding v8

description: Hyphema and/or massive vitreous hemorrhage. (from AJCC 8th Ed.)


Retinoblastoma cT1b TNM Finding v8

description: Tumors more than 3 mm or closer than 1.5 mm from disc and fovea. (from AJCC 8th Ed.)


A carboxyalkyl phosphate consisting of D-glyceric acid having an alpha-D-glucosyl residue at the 2-position and a phospho group at the 3-position


D-glucosyl-N-hexanoylsphingosine

A D-glucosyl-N-acylsphingosine in which the ceramide N-acyl group is specified as hexanoyl.


name: Malignant neoplasm overlapping retroperitoneum and peritoneum sites

description: Evidence of a malignant neoplasm of overlapping sites of the retroperitoneum and peritoneum.


The zwitterion formed by transfer of a proton from the OH of the phospho group to the alanyl amino nitrogen.


A zwitterion obtained by transfer of a proton from the phosphate to the amino group of any 1,2-diacyl-sn-glycero-3-phospho-1'-(3'-O-L-alanyl)-sn-glycerol.


hydramacrophyllol A

An isobenzofuranone that is 2-benzofuran-1(3H)-one substituted by a hydroxy group at position 7 and a (S)-hydroxy(4-hydroxyphenyl)methyl group at position 3. It has been isolated from the roots of Scorzonera judaica.


An amino acid zwitterion arising from transfer of a proton from the carboxy to the amino group of 4-(3-methylbut-2-enyl)-L-abrine.


cryptocyanin cation

A cationic C3-cyanine type compound with 1-ethylquinolin-4-yl groups at both ends.


3-O-beta-D-glucosyl-D-glucuronic acid

A disaccharide consisting beta-D-glucosyl and D-glucuronic acid residues joined by a (1->3)-linkage.


Bone Mineral Content

description: An assessment of the quantity of minerals within a specific bone.


Refractory Hairy Cell Leukemia Variant

description: Hairy cell leukemia variant that is resistant to treatment.


name: HHV-8-Associated Multicentric Castleman Disease

description: Multicentric Castleman disease associated with HHV8 infection.


Testicular Cancer pTis TNM Finding v8

description: Testicular cancer with a finding of germ cell neoplasia in situ. (from AJCC 8th Ed.)


A deoxypentose that is D-ribofuranose in which the hydroxy group at position C-2 is replaced by hydrogen.


Sellar Chondroid Chordoma

description: A chondroid chordoma that arises from the sellar region.


Conventional Chordoma

description: A malignant bone tumor arising from the remnants of the fetal notochord. It is characterized by the presence of large epithelioid cells with clear to light eosinophilic cytoplasm. Some of the cells are large with bubbly, vacuolated cytoplasm (physaliphorous cells). The cells form cords and nests that are embedded within an extracellular myxoid matrix.


A thiohydroximic acid in which the C-substituent is specified as (3-indolyl)methyl (the E-geoisomer).


Grade 1 Abducens Nerve Disorder, CTCAE

description: Asymptomatic; clinical or diagnostic observations only; intervention not indicated


A glycophytoceramide having an alpha-D-galactopyranosyl residue at the O-1 position and a 15-phenylpentadecanoyl group attached to the nitrogen.


(E)-hex-2-enyl acetate

An acetate ester resulting from the formal condensation of the hydroxy group of (E)-hex-2-en-1-ol with the carboxy group of acetic acid.


An N-acyl-L-alanine resulting from the formal condensation of the amino group of L-alanine with the carboxy group of (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoic acid.


dicamba-methyl

The methyl ester of dicamba.